Takeda Pharmaceutical is increasing its prospects in hematology with a deal for the rights to a drug that’s advancing into pivotal testing in a sort of blood most cancers, giving the Japanese pharmaceutical big an asset that would doubtlessly compete with blockbuster Bristol Myers Squibb -product. Takeda will get elritercept, Keros Therapeutics' lead drug candidate. Beneath the phrases of the […]